Disease Attributes clinical trials
The registry lists 21 studies for Disease Attributes across more than 10 countries. 7 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-11-03.
Get an email when these change. Save the Disease Attributes studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
University of Colorado, Denver (3) · AusperBio Therapeutics Inc. (2) · University of Virginia (1) · University of North Carolina, Chapel Hill (1) · Servier (1) · British Columbia Cancer Agency (1) · Medtronic Vascular (1) · Orca Biosystems, Inc. (1)
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3
- May 2027Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions · AusperBio Therapeutics Inc.
- Jul 2027Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) · National Cancer Institute (NCI)
- Nov 2027Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome · Orca Biosystems, Inc.
Who these studies take
Of the 5 Disease Attributes studies recruiting now, 2 (40%) set no upper age limit and 2 (40%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 5 (100%) | 5 (100%) |
| 30 | 5 (100%) | 5 (100%) |
| 40 | 5 (100%) | 5 (100%) |
| 50 | 5 (100%) | 5 (100%) |
| 65 | 5 (100%) | 5 (100%) |
| 75 | 3 (60%) | 3 (60%) |
| 85 | 2 (40%) | 2 (40%) |
Across all 21 studies, recruiting or not: 19% stop at 75 or younger and 19% at 65; 10% take children; 0% are for women only and 10% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 12, 2026.
Results posted1
- Strategy to Avoid Excessive Oxygen Using an Autonomous Oxygen Titration InterventionOct 14, 2026NCT06374225
Studies
Recruiting first, then most recently updated. Showing 21 of 21. search them.
- Long-Term Clinical, Health Economic, and Process Evaluation of Intensive Technology-Integrated Motor Rehabilitation in Chronic Neurological Conditions (INTeRAcT-bis)Enrolling by invitationNCT07912320Not applicable1 country
- Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe RegionsRecruitingNCT07654283Phase 26 countries
- SPYRAL GEMINI Pilot StudyRecruitingNCT06907147Not applicable6 countries
- Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific RegionRecruitingNCT07370207Phase 27 countries
- Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell LymphomaRecruitingNCT05826535Phase 1/22 countries
- Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeRecruitingNCT07216443Phase 21 country
- Disease Characteristics of R-CADNot yet recruitingNCT07239921
- Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)Active, not recruitingNCT05797246Phase 21 country
- Strategy to Avoid Excessive Oxygen Using an Autonomous Oxygen Titration InterventionCompletedNCT06374225Not applicable1 country
- Vorasidenib Expanded Access ProgramApproved for marketingNCT05592743
- Strategy to Avoid Excessive Oxygen in Major Burn PatientsActive, not recruitingNCT04534972Phase 31 country
- Strategy to Avoid Excessive Oxygen for Critically Ill Trauma PatientsActive, not recruitingNCT04534959Phase 31 country
- Enabling Personalized Medicine Through Exome Sequencing in the U.S. Air ForceCompletedNCT03276637Not applicable1 country
- ASPIRIN Trial BelgiumActive, not recruitingNCT03464305Phase 31 country
- Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's DiseaseActive, not recruitingNCT02332356Phase 31 country
- Continuous and Wireless Vital Sign Monitoring in Patients at Home After Acute Medical AdmissionCompletedNCT055362061 country
- 68Ga-HTK03149 for Use as a Diagnostic RadiopharmaceuticalStatus unknownNCT04831307Not applicable1 country
- Prediction of Functional Outcomes From Chronic Critical IllnessCompletedNCT031592081 country
- Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly DiagnosedStatus unknownNCT04462926Not applicable1 country
- Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCTStatus unknownNCT03114670Phase 11 country
- Medications Development for the Treatment of Cannabis Related DisordersCompletedNCT01204723Phase 11 country